Special Issue "Advances in Pancreatic Cancer Imaging"
Deadline for manuscript submissions: 31 January 2022.
Pancreatic cancer is the fourth most common cause of cancer-related deaths in developed countries. To improve outcomes, there is a critical need for improved tools for detection, accurate staging, and resectability assessment. This could improve patient stratification for the most optimal primary treatment modality. Current clinical imaging protocols of pancreatic cancer include transabdominal ultrasound, computed tomography (CT) and/or magnetic resonance (MR) imaging for disease staging and prediction of resectability. Currently, multidetector CT is the technique of choice for the study of pancreatic tumors. On the other hands, MR imaging plays an important role in the assessment of pancreatic cancer. Its superior soft tissue contrast is useful in the detection of small, non-contour-deforming tumors and for characterizing indeterminate pancreatic findings at computed tomography. Such techniques may include magnetic resonance imaging with diffusion-weighted sequences or hepatobiliary contrast agents, perfusion imaging, or molecular imaging with radiolabelled tracers. Endoscopic ultrasound (EUS) can complement these imaging methods with valuable staging information as well as the opportunity of tissue diagnosis by fine-needle aspiration. Molecular functional imaging has the potential to play an important role in pancreatic cancer management.
This Special Issue of Cancers will cover state-of-the-art and future developments in clinical imaging of pancreatic cancer. We are inviting original research articles, reviews, and perspectives, to address some of these challenges for imaging of pancreatic cancer. We hope to discuss their current application to the management of patients with pancreatic cancer, and anticipate future developments within this field.
Dr. Masakatsu Tsurusaki
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- hepatobiliary cancer
- early diagnosis
- CT/ MRI
- preoperative imaging
- tumor grading/heterogeneity
- tumor progression
- post-therapeutic changes
- treatment response